Related Experiment Video
Updated: Apr 17, 2026

In Vitro Differentiation Model of Human Normal Memory B Cells to Long-lived Plasma Cells
Published on: January 20, 2019
MCPH1 maintains long-term epigenetic silencing of ANGPT2 in chronic lymphocytic leukemia
Pradeep Kumar Kopparapu1, Caroline Miranda1, Linda Fogelstrand1
1Department of Clinical Chemistry and Transfusion Medicine, Institute of Biomedicine, Sahlgrenska Academy, Gothenburg University, Sweden.
Abstract:
The microcephalin gene (MCPH1) [also known as inhibitor of human telomerase reverse transcriptase (hTERT) expression] is a tumor suppressor gene that is functionally involved in the DNA damage response. Angiopoietin 2 (ANGPT2) is a crucial factor regulating tumor angiopoiesis. Deregulation of angiogenesis is one of the hallmarks of many cancers, including chronic lymphocytic leukemia (CLL). In CLL, ANGPT2 is a well-studied potential prognostic marker. As MCPH1 overlaps with the ANGPT2 transcription unit on the same chromosome but in the opposite orientation, we wanted to study the functional role of MCPH1 in regulation of ANGPT2 in CLL. The mRNA expression levels of MCPH1 and ANGPT2, including the MCPH1 target gene hTERT, showed significant differences between two prognostic groups, i.e. IGHV-mutated and IGHV-unmutated (P = 0.007 for MCPH1, P = 0.0002 for ANGPT2, and P = 0.00001 for hTERT), in which the expression level of MCPH1 was inversely correlated with the expression levels of hTERT and ANGPT2. Downregulation of MCPH1 resulted in upregulation of ANGPT2, accompanied by loss of its promoter methylation. Using chromatin immunoprecipitation and coimmunoprecipitation assays, we found that MCPH1 binds to the ANGPT2 promoter and recruits DNA methyltransferases, thereby silencing ANGPT2. Thus, our data suggest a novel function for MCPH1 in regulating and maintaining ANGPT2 silencing in CLL through regulation of promoter DNA methylation.
Insights
Microcephalin (MCPH1), a tumor suppressor, regulates Angiopoietin 2 (ANGPT2) in chronic lymphocytic leukemia (CLL). MCPH1 silences ANGPT2 by recruiting DNA methyltransferases, impacting cancer prognosis.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Genetics
Background:
- Deregulation of angiogenesis is a hallmark of cancers, including chronic lymphocytic leukemia (CLL).
- Angiopoietin 2 (ANGPT2) is a key regulator of tumor angiogenesis and a prognostic marker in CLL.
- Microcephalin (MCPH1), a tumor suppressor involved in DNA damage response, is located on the same chromosome as ANGPT2.
Purpose of the Study:
- To investigate the functional role of MCPH1 in regulating ANGPT2 expression in CLL.
- To explore the mechanism by which MCPH1 influences ANGPT2 in the context of CLL prognosis.
Main Methods:
- Analysis of mRNA expression levels of MCPH1, ANGPT2, and hTERT in CLL prognostic groups.
- Chromatin immunoprecipitation (ChIP) and coimmunoprecipitation assays.
- Assessment of promoter DNA methylation of ANGPT2.
Main Results:
- MCPH1, ANGPT2, and hTERT mRNA expression levels differed significantly between IGHV-mutated and IGHV-unmutated CLL prognostic groups.
- MCPH1 expression inversely correlated with hTERT and ANGPT2 expression.
- Downregulation of MCPH1 led to ANGPT2 upregulation and loss of its promoter methylation.
- MCPH1 binds to the ANGPT2 promoter and recruits DNA methyltransferases to silence ANGPT2.
Conclusions:
- MCPH1 plays a novel role in regulating and maintaining ANGPT2 silencing in CLL.
- MCPH1's mechanism involves the regulation of ANGPT2 promoter DNA methylation.
- This finding provides new insights into the molecular mechanisms underlying CLL pathogenesis and prognosis.
More Related Videos
Related Concept Videos
Abnormal Proliferation
Epigenetic Regulation
X-chromosome...
Epigenetic Regulation
Inheritance of Chromatin Structures
Non-LTR Retrotransposons

